Search trials – HealthDB

Активни: Recruiting ×

Намерени 4,436 изпитвания Стр. 100 от 222

Recruiting Phase 4

Optimising TREATment for Severe Gram-Negative Bacterial Infections

Bloodstream Infection Ventilator Associated Bacterial Pneumonia Hospital Acquired Bacterial Pneumonia Carbapenem Resistant Bacterial Infection +1

TREAT-GNB is an innovative trial to expedite the evaluation of various antibiotic choices and treatment strategies for severe multidrug-resistant Gram-negative bacterial infections, specifically bloodstream and lower respiratory tract infections. This approach combines platform trial elements with adaptive clinical designs to streamline the evaluation of various treatment options and optimise resource utilisation. The overall aim of the TREAT-GNB platform trial is to identify interventions that improve survival in patients with severe infections due to Gram-negative bacteria. In the CR-GNB silo of TREAT-GNB, the primary objective is to quantify the effect on all-cause mortality at 28 days of a range of interventions in patients with bloodstream infections, ventilator-associated pneumonia, and hospital-acquired pneumonia caused by CR-GNB.

Начало: 21.04.2025 Край: 31.12.2028 Възраст: от 18 г. Treatment

Australia, China, Lebanon +9 National University of Singapore NCT07004049

Recruiting Phase 4

Seizure Prevention in Traumatic Brain Injury With Levetiracetam and Lacosamide

Traumatic Brain Injury

The purpose of this study is to assess the incidence of early post-traumatic seizures. The study will also assess the benefit of lacosamide compared to levetiracetam in regards to agitation and behavioral adverse effects in patients with traumatic brain injury requiring seizure prophylaxis.

Начало: 18.04.2025 Край: 01.04.2027 Възраст: от 18 г.

United States Wake Forest University Health Sciences NCT06866691

Recruiting

Metabolic Impact and Compliance of Controlled, Varying, Mediterranean Diets in Pre-Surgical Prostate Cancer Populations (PROVISIONS)

Prostate Cancer

The study aims to investigate whether following a controlled Mediterranean-style diet prior to robotic-assisted radical prostatectomy surgery in patients diagnosed with prostate cancer affects fasting insulin levels and other values that can be measured in blood and tissue samples from surgery.

Начало: 17.04.2025 Край: 01.05.2027 Възраст: 18–80 г.

United States University of Miami NCT06487507

Recruiting Phase 3

A Trial to Investigate Benralizumab in Children With Eosinophilic Diseases

Eosinophilic Granulomatosis With Polyangiitis (EGPA) Hypereosinophilia Syndrome (HES)

The main purpose of study is to assess the safety, tolerability, pharmacokinetics (PK), and efficacy of benralizumab.

Начало: 17.04.2025 Край: 03.04.2028 Възраст: 6–17 г.

Brazil, Canada, France +7 AstraZeneca NCT06512883

Recruiting

Pooled Analysis of Single-arm Studies of Budesonide/Glycopyrronium/Formoterol (BGF) in Routine Care Setting

Pulmonary Disease, Chronic Obstructive

The CHOROS pooled analysis is a retrospective secondary data use analysis of integrated individual participant data from a series of planned and on-going primary prospective, non-interventional, multi-center studies sponsored by AstraZeneca and conducted in the pulmonary/primary care practitioner setting in multiple countries and may include data from the following countries: United Kingdom, Germany, Italy, Greece, Japan, Canada and Romania.

Начало: 17.04.2025 Край: 14.12.2026 Възраст: от 18 г.

Canada, Germany, Greece +4 AstraZeneca NCT06712563

Recruiting Phase 1

A Comparative Study of Pharmacokinetics, Safety, and Immunogenicity of RPH-030 and Vectibix® in Patients With Metastatic Colorectal Cancer With Wild-type RAS as First-line Therapy in Combination With FOLFIRI

Metastatic Colorectal Cancer

The primary objective of this study is to demonstrate equivalence of pharmacokinetic properties, and comparability of safety and immunogenicity parameters of RPH-030 and Vectibix® following a single (first) intravenous administration to patients with mCRC with wild-type RAS genes as 1-line therapy in combination with FOLFIRI. The additional objective is to perform a pilot evaluation of the efficacy of RPH-030 and Vectibix® following a single (first) intravenous administration to patients with mCRC with wild-type RAS genes as 1-line therapy in combination with FOLFIRI.

Начало: 17.04.2025 Край: 01.08.2028 Възраст: от 18 г.

Russia R-Pharm NCT07543744

Recruiting Phase 2

An Extension Study of Subjects Who Received an Avalyn Inhaled Antifibrotic Agent (SAIL)

Progressive Pulmonary Fibrosis Idiopathic Pulmonary Fibrosis (IPF)

This is an open-label extension study for participants who were previously enrolled in and completed an Avalyn Pharma Sponsored study with an inhaled antifibrotic, such as AP01. Eligible participants will have their final dose of drug at the end of study visit from the lead-in study and first AP-LTE-008 study visit on the same day.

Начало: 17.04.2025 Край: 31.12.2031 Възраст: от 18 г. Treatment

Australia, Canada, Czechia +8 Avalyn Pharma Inc. NCT06951217

Recruiting Phase 3

A Phase 3 Study of Ersodetug in Patients With Tumor Hyperinsulinism

Tumor Hyperinsulinism (Tumor HI)

The objectives of this study are to evaluate the glycemic efficacy, safety, and tolerability of ersodetug as add-on to standard of care (SOC) therapy for treatment of hypoglycemia in patients with Tumor Hyperinsulinism (Tumor HI).

Начало: 16.04.2025 Край: 01.09.2027 Възраст: от 18 г.

France, Netherlands, Switzerland +2 Rezolute NCT06881992

Recruiting

The Foods & Oil to Repair, Correct and Enhance Strength (FORCES) Study

Sarcopenia

The proposed research is a parallel arm, randomized placebo-controlled clinical trial designed to assess changes in muscle strength, volume, fatigue resistance, and mobility in older adults after daily consumption of 12g of linoleic acid-rich oil.

Начало: 16.04.2025 Край: 01.05.2030 Възраст: 65–80 г.

United States Ohio State University NCT06361511

Recruiting

GEneRating Mucosal Immunity After INfluenzA Infection and Vaccination in Lung and Lymphoid TissuE

Influenza

This experimental medicine study aims to compare immune responses in healthy adult volunteers aged 18-55 years against influenza vaccination and infection in the upper and lower respiratory tract, following administration of a live-attenuated influenza vaccine delivered by nasal spray versus influenza A (H3N2) viral challenge.

Начало: 16.04.2025 Край: 31.07.2026 Възраст: 18–55 г.

United Kingdom Imperial College London NCT06620185

Recruiting Phase 2

A Study to Investigate Multiple Sclerosis Relapse Prevention With mRNA-1195 Compared With Placebo in Participants Aged 18 to ≤55 Years

Multiple Sclerosis

The primary objective of this trial is to evaluate the safety and reactogenicity of mRNA-1195 in participants with multiple sclerosis.

Начало: 16.04.2025 Край: 08.01.2029 Възраст: 18–55 г. Treatment

Australia, United Kingdom, United States ModernaTX, Inc. NCT06735248

Recruiting Phase 3

Long-Term Study to Assess the Safety and Tolerability of NBI-1065845 as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD)

Major Depressive Disorder

This study will evaluate the long-term safety and tolerability of NBI-1065845 as an adjunctive treatment in participants with MDD.

Начало: 16.04.2025 Край: 01.05.2030 Възраст: от 18 г.

Belgium, Bulgaria, Croatia +13 Neurocrine Biosciences NCT06966401

Recruiting Phase 2

An open-label extension study evaluating the safety of zagociguat in participants with MELAS who completed TIS6463-203

Mitochondrial encephalomyopathy lactic acidosis and stroke-like episodes (MELAS)

Trial status: Authorised Vital sign measurements, ECG assessments, clinical laboratory tests, and C-SSRS responses at each scheduled timepoint, DEXA hip and lumbar spine BMD at each scheduled timepoint, Concentrations of CTX and P1NP at each scheduled timepoint, Incidence of SLE. Time to first SLE from Day 1, NMDAS scores at each scheduled timepoint, Concentrations of lactate, GDF-15, FGF-21, B2M, serum amyloid P component, TNFR-2, vWF, ICAM-1, NfL, and VCAM-1 at each scheduled timepoint, CGI-C overall MELAS scale score at each scheduled timepoint, eGFR and UACR at each scheduled timepoint, HbA1c level at each scheduled timepoint, Concentrations of troponin I, NT-proBNP, and creatine kinase (CK)-MB at each scheduled timepoint, Exploratory pharmacokinetics: Concentrations of zagociguat at each scheduled time point Incidence of treatment-emergent adverse events (TEAEs)

Начало: 16.04.2025 Възраст: от 18 г.

Germany, Italy Tisento Therapeutics Inc. 2024-517514-15-00

Recruiting

Food Challenge at Home or in Medical Practice - the FoodCHOMP Study

Food Allergies

This is a pilot, multi-centre, randomised clinical trial evaluating the safety and feasibility of a home-based oral food challenge in adults with low-risk food allergy labels. Eligible participants are aged 18 years or older and have a self-reported food allergy with negative skin prick testing to the implicated food. Participants will be randomised to either a home-based or standard in-clinic food challenge. The primary aim is to determine the safety of home challenges, measured by the rate of immune-mediated adverse events. Secondary aims include feasibility of recruitment and delivery, protocol adherence, quality of life, and food reintroduction outcomes.

Начало: 16.04.2025 Край: 01.12.2026 Възраст: от 18 г. Diagnostic

Australia Austin Health NCT06916819

Recruiting

Benefits of Choir for Older Adults With Unaddressed Hearing Loss (WP2)

Hearing Loss, Age-Related Speech Intelligibility Psychosocial Functioning

Unaddressed age-related hearing loss is highly prevalent among older adults, typified by negative consequences for speech-in-noise perception and psychosocial wellbeing. There is promising evidence that group singing may enhance speech-in-noise perception and psychosocial wellbeing. However, there is a lack of robust evidence, primarily due to the literature being based on small sample sizes, single site studies, and a lack of randomized controlled trials. Hence, to address these concerns, this SingWell Project study utilizes an appropriate sample size, multisite, randomized controlled trial approach, with a robust preplanned statistical analysis. The objective of the study is to explore if group singing may improve speech-in-noise perception and psychosocial wellbeing for older adults with unaddressed hearing loss. The investigators designed an international, multisite, randomized controlled trial to explore the benefits of group singing for adults aged 60 years and older with unaddressed hearing loss. After undergoing an eligibility screening process and completing an information and consent form, the investigators intend to recruit 210 participants that will be randomly assigned to either group singing or an audiobook club (control group) intervention for a training period of 12-weeks. The study has multiple timepoints for testing, that are broadly categorized as macro (i.e., pre- and post-measures across the 12-weeks), or micro timepoints (i.e., pre- and post-measures across a weekly training session). Macro measures include behavioural measures of speech and music perception, and psychosocial questionnaires. Micro measures include psychosocial questionnaires and heart-rate variability. The investigators hypothesize that group singing may be effective at improving speech perception and psychosocial outcomes for older adults with unaddressed hearing loss-more so than participants in the control group.

Начало: 15.04.2025 Край: 01.09.2026 Възраст: от 60 г. Treatment

Australia, Canada, Germany +2 Toronto Metropolitan University NCT06580847

Recruiting Phase 3

A Study Using Risk Factors to Determine Treatment for Children With Favorable Histology Wilms Tumors (FHWT)

Stage I Mixed Cell Type Kidney Wilms Tumor Stage II Mixed Cell Type Kidney Wilms Tumor Stage III Mixed Cell Type Kidney Wilms Tumor Stage IV Mixed Cell Type Kidney Wilms Tumor

This phase III trial studies using risk factors in determining treatment for children with favorable tissue (histology) Wilms tumors (FHWT). Wilms Tumor is the most common type of kidney cancer in children, and FHWT is the most common subtype. Previous large clinical trials have established treatment plans that are likely to cure most children with FHWT, however some children still have their cancer come back (called relapse) and not all survive. Previous research has identified features of FHWT that are associated with higher or lower risks of relapse. The term "risk" refers to the chance of the cancer coming back after treatment. Using results of tumor histology tests, biology tests, and response to therapy may be able to improve treatment for children with FHWT.

Начало: 15.04.2025 Край: 13.02.2031 Възраст: до 30 г. Treatment

Australia, Canada, United States Children's Oncology Group NCT06401330

Recruiting

Cognitive Bias Modification for Interpretation (CBM-I) in People With Type 2 Diabetes and Persistent Pain

Type 2 Diabetes Persistent Pain

The goal of this clinical trial is to examine the efficacy of cognitive bias modification for interpretation (CBM-I) in people with Type 2 Diabetes and persistent pain. The main question\[s\] it aims to answer is whether interpretation bias training away from pain improves pain outcomes. Participants in the CBM-I group will complete 4 online training sessions approximately half an hour each. Each session will present participants with ambiguous scenarios which may be pain-related, however the final word of the sentence will resolve the scenario as benign (thus training participants to make benign interpretations). A measure of interpretation bias will be administered following the fourth training session, and pain severity and interference will be measured at baseline, post-training, two week follow up, and three month follow up. The study hypothesises that participants in the CBM-I group will demonstrate a greater reduction in the co-primary outcomes of pain severity and pain interference over time compared to those in the placebo control.

Начало: 15.04.2025 Край: 15.10.2025 Възраст: от 18 г. Treatment

Australia University of Sydney NCT06908486

Recruiting

Breathing Patterns in Infants Before and After Extubation

Respiratory Distress Syndrome (RDS) PreTerm Neonate

The primary objective of this study is to compare work of breathing indices before and after extubation in intubated premature infants admitted to the Christiana Care Neonatal Intensive Care Unit. The secondary objective is to compare the ability of work of breathing indices to predict extubation failure to routine spontaneous breathing tests (SBTs) in intubated premature infants admitted to the ChristianaCare NICU.

Начало: 14.04.2025 Край: 01.12.2026 Възраст: до 6 г.

United States Christiana Care Health Services NCT07542301

Recruiting

EXtubation Related Complications - the EXTUBE Study (EXTUBE)

Extubation

EXTUBE is an international, multicentre, prospective cohort study evaluating the incidence, risk factors, and outcomes of extubation-related complications and describing clinical practices related to extubation after general anesthesia or after critical illness in the operating room (OR), out of OR anesthesia location or intensive care unit (ICU).

Начало: 14.04.2025 Край: 01.12.2026 Възраст: от 18 г.

Australia, Canada, Ireland +4 University Health Network, Toronto NCT06442930

Recruiting Phase 2

Pharmacogenomics for Better Treatment of Fungal Infections Clinical Trial

Fungal Infection Haematological Malignancy Blood Cancer Infectious Disease

This project aims to address invasive fungal infections in patients, by precision dosing of voriconazole based on CYP2C19 genotype testing with Bayesian dose-forecasting dosing software to develop patient-centric and maximally effective dosing regimens. This study investigates if voriconazole increases the proportion of patients achieving therapeutic exposure at day 8 of dosing compared with standard care; and will assess factors that influence the implementation of genotype testing and dosing software in the healthcare system, including fidelity, feasibility, acceptability and cost-effectiveness. It will recruit at least 104 kids and adults in a parallel-group randomised clinical trial. A hybrid feasibility sub-study will assess the scalability of genotype-directed dosing to ensure sustainable integration of the interventions into the clinical workflow. A health economic sub-study will evaluate the costs, health outcomes and cost-effectiveness of genotype-directed testing compared to standard care.

Начало: 14.04.2025 Край: 26.03.2027 Възраст: от 2 г. Treatment

Australia, United States The University of Queensland NCT06510699

1 … 98 99 100 101 102 … 222